Endogenous serum testosterone in males after different doses and routes of administration of medroxyprogesterone acetate.
The effects of different doses and routes of administration (oral and IM) of medroxyprogesterone acetate on endogenous testosterone secretion were studied in healthy male volunteers. There were three treatment groups. Serum testosterone levels, measured by radioimmunoassay before, during and after different doses of medroxyprogesterone acetate, were significantly lowered (p < 0.05) in these subjects. A tendency to return toward pretreatment values was noted within three to six weeks after the last dose of medroxyprogesterone acetate. The IM route of administration suppressed the testosterone levels for the longest period of time. No indication of drug-induced toxicity, as judged by vital signs, systemic side effects, standard laboratory evaluations and some special clinical evaluations, was found during treatment or in the period immediately following the course of therapy. No serious or untoward side effects were encountered.
D000284:Administration, Oral; D000328:Adult; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008525:Medroxyprogesterone / Q000008:administration & dosage* / Q000494:pharmacology; D011863:Radioimmunoassay; D013739:Testosterone / Q000097:blood / Q000378:metabolism*
D013739:Testosterone; D008525:Medroxyprogesterone